FNArena Windows
Introduction to FNArena Windows
FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.
Latest Stories
The FNArena Editor shares his views on investing, AI, Australian shares and about what to expect from the August results season
10:00 AM
While one broker has turned more cautious on ResMed due to a one-off cost and risk of rising competition, analysts broadly welcome the MatrixCare sale as a strategic refocus backed by a sizeable shareholder return
Jul 14 2026
| ASX CODE | LAST PRICE | % MOVE | 52WK HIGH | 52WK LOW | P/E | CONSENSUS TARGET | UPSIDE/DOWNSIDE |
|---|---|---|---|---|---|---|---|
| 4DX | $3.91 |
|
$7.55 | $0.47 | -22.0 |
$4.50 |
|
| AT1 | $0.02 | 0.00% | $0.05 | $0.02 |
|
||
| AVE | $0.02 | 0.00% | $0.03 | $0.01 |
|
||
| BB1 | $0.67 |
|
$1.11 | $0.48 |
$1.76 |
|
|
| BRN | $0.14 |
|
$0.27 | $0.11 |
|
||
| CAT | $3.61 |
|
$7.72 | $2.74 |
$5.134 |
|
|
| CBL | $0.06 | 0.00% | $0.10 | $0.03 |
|
||
| CGS | $2.74 |
|
$3.01 | $1.65 | 29.8 |
$3.70 |
|
| CMP | $0.23 | 0.00% | $0.45 | $0.22 |
|
||
| COH | $133.93 |
|
$313.27 | $88.74 | 28.6 |
$114.028 |
|
| CSX | $0.40 | 0.00% | $0.85 | $0.32 |
|
||
| CTE | $1.25 |
|
$1.31 | $0.74 |
|
||
| CU6 | $2.80 |
|
$5.87 | $1.80 |
$6.40 |
|
|
| CVB | $0.02 | 0.00% | $0.18 | $0.02 |
|
||
| EBR | $0.30 |
|
$1.47 | $0.24 |
$1.585 |
|
|
| EIQ | $1.60 |
|
$1.88 | $0.17 |
$1.867 |
|
|
| EMV | $1.73 |
|
$2.43 | $1.47 |
$3.15 |
|
|
| EYE | $0.16 | 0.00% | $0.21 | $0.10 |
|
||
| FPH | $35.26 |
|
$35.92 | $26.51 | 13.6 |
|
|
| IME | $0.32 | 0.00% | $0.47 | $0.22 | 15.2 |
$0.50 |
|
| IMR | $2.05 |
|
$2.25 | $1.28 |
$2.90 |
|
|
| IPD | $0.01 | 0.00% | $0.06 | $0.00 |
$0.015 |
|
|
| LDX | $0.12 | 0.00% | $0.33 | $0.08 |
$0.25 |
|
|
| MX1 | $0.03 | 0.00% | $0.12 | $0.03 |
$0.08 |
|
|
| NAN | $3.55 |
|
$4.77 | $2.94 | 63.4 |
$3.80 |
|
| ONE | $0.16 | 0.00% | $0.41 | $0.13 |
$0.42 |
|
|
| PCK | $0.10 |
|
$0.35 | $0.04 |
|
||
| PEB | $0.22 | 0.00% | $0.27 | $0.09 |
|
||
| PGC | $0.13 | 0.00% | $0.41 | $0.13 | 10.0 |
$0.25 |
|
| PME | $183.71 |
|
$324.49 | $107.75 | 124.1 |
$221.667 |
|
| RAP | $0.03 | 0.00% | $0.07 | $0.02 |
|
||
| RMD | $31.80 |
|
$45.25 | $25.50 | 17.9 |
$38.875 |
|
| SHG | $0.19 | 0.00% | $0.36 | $0.17 |
|
||
| SOM | $0.37 |
|
$0.95 | $0.37 | 23.1 |
$0.75 |
|
| TRJ | $0.19 | 0.00% | $0.95 | $0.19 | 10.3 |
$0.825 |
|
-5.10% 
15.1% Previous Stories
A Technical Breakout For ResMed
Jul 07 2026
ResMed appears to have formed a technical bottom after breaking above key resistance, Fairmont Equities’ Michael Gable reports
Awaiting Catapult Sports’ Fundamental Re-Rating
Jun 15 2026
Following a stand-out FY26, analysts believe Catapult Sports’ execution and growth trajectory suggest a re-rating should follow
Treasure Chest: Pro Medicus
Jun 04 2026
FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. Today’s idea is Pro Medicus
Cochlear’s Shock Downgrade Raises Concerns
Apr 23 2026
Cochlear’s shock downgrade has challenged the long-held assumption the company is immune to economic cycles
GLP-1s Drive Strong Quarter For ResMed
Feb 02 2026
It was once feared weight-loss drugs would crush demand for sleep apnoea products. ResMed’s December quarter has shown very much the opposite is true
ImpediMed Ready To Scale Up
Dec 16 2025
It’s been a long road for medical device manufacturer ImpediMed, but analysts believe the company is now ready to increase scale
Fisher & Paykel Healthcare’s Superior Profile
Dec 02 2025
Fisher & Paykel Healthcare’s first half saw lower costs overcoming a drag from US tariffs. Declining US vaccination rates could provide a boost in the second half
4DMedical Poised For A Recovery
Nov 25 2025
Michael Gable of Fairmont Equities notes 4DMedical shares retraced from a new October high and the bounce supports a move higher
Treasure Chest: Pro Medicus
Nov 12 2025
FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. Today’s idea is Pro Medicus
Tariff Uncertainty Negates ResMed’s Q1 Positives
Nov 05 2025
ResMed’s first-quarter result broadly met market expectations, though rising margins and potential for further capital management have been negated by US import tariff ambiguity